A

Avalo Therapeutics
D

AVTX

18.710
USD
-0.80
(-4.10%)
مغلق
حجم التداول
14,004
الربح لكل سهم
-7
العائد الربحي
-
P/E
-1
حجم السوق
339,286,541
الأخبار المقالات

العنوان: Avalo Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).